2016.12.05 update

【News】CYBERDYNE invests in Kringle Pharma, Inc., a R&D company of HGF medicine
~ to establish a new combination treatment with HAL and medicament for patients of spinal cord injury, ALS and other diseases~

CYBERDYNE, Inc. (the “Company”) determined to invest in Kringle Pharma, Inc. (Head office: Osaka, Japan: CEO: Kunio Iwatani, “KRINGLE”) subscribing to the KRINGLE’s capital increase through third-party allocation as set forth below. 

KRINGLE is known for its development of medicament, based on its research of “recombinant human Hepatocyte Growth Factor” (“rhHGF”). Hepatocyte Growth Factor (“HGF”) is considered as an intrinsic factor with an organotrophic role in the repair and regeneration of various tissues and organs, and is thought to have significant potential in becoming an innovative medicine for many intractable diseases. KRINGLE is currently working on a clinical trial for intractable neurological disease (eg. acute stage spinal cord injury and ALS) in Japan.

The Company intends to combine “Cybernic treatment with HAL for Medical Use (Lower Limb)” and HGF medicine, in order to establish a new method of treatment, which would improve and regenerate the physical function of patients suffering from spinal cord injuries, ALS and other diseases.

For more information please visit

Kringle Pharma’s project entitled ‘Recombinant human HGF for the treatment of acute spinal cord injury’ was accepted by Japan Agency for Medical Research and Development, AMED, as its Drug Discovery Support Promotion Project. (In Japanese only)

An investigator-initiated Phase II clinical trial of recombinant human HGF started at the Tohoku and Osaka University Hospitals for the treatment of amyotrophic lateral sclerosis (ALS). (In Japanese only)

KRINGLE Initiates Phase I/II Clinical Trial of Recombinant Human HGF for the Treatment of Acute Spinal Cord Injury.